计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E414124-1mg |
1mg |
现货 ![]() |
| |
| E414124-5mg |
5mg |
期货 ![]() |
| |
| E414124-10mg |
10mg |
现货 ![]() |
| |
| E414124-25mg |
25mg |
现货 ![]() |
| |
| E414124-50mg |
50mg |
现货 ![]() |
| |
| E414124-100mg |
100mg |
现货 ![]() |
| |
| E414124-250mg |
250mg |
现货 ![]() |
|
| 英文别名 | 4-Benzofurancarboxamide,N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-ethyl-6-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-2-[1-(1-methylethyl)-4-piperidinyl]- |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | EBI-2511 |
| 生化机理 | EBI-2511 是一种高效口服活性 EZH2 抑制剂,对 EZH2(A667G) 的 IC50 值为 4 nM。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 泽斯特增强子 2 多聚酶抑制复合体 2 亚基抑制剂 |
| 产品介绍 |
Information EBI-2511 EBI-2511 is a highly potent and orally active EZH2 inhibitor with an IC50 of 4 nM for EZH2(A667G). Targets EZH2(A667G) (Cell-free assay) 4 nM In vivo In in vivo experiments, rats are administrated with dosages of 5 mg/kg EBI-2511 (p.o.) and 0.5 mg/kg EBI-2511 (i.v.). Mice are administrated with dosages of 10 mg/kg p.o. and 1.0 mg/kg i.v. For i.v. administration, the clearance of EBI-2511 is modest with CLz/F of 26 and 32 mL/min/kg in rats and mice, respectively. After a single 5 and 10 mg/kg oral dose of a CMC-Na suspension of EBI-2511 to rats and mice, its AUC0‑t reaches 239 and 774 ng/mL·h with oral bioavailability of 9% and 16%, respectively. plasma protein binding of EBI-2511 in human, rat, and mouse are 93.9%, 94.0%, and 92.7%, respectively. Cell Research(from reference) Cell lines:Pfeiffer cells Incubation Time:5 days |
| 纯度 | ≥98% |
| ALogP | 4.484 |
|---|---|
| hba_count | 4 |
| HBD Count | 2 |
| Rotatable Bond | 9 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504773140 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-ethyl-6-[ethyl(oxan-4-yl)amino]-2-(1-propan-2-ylpiperidin-4-yl)-1-benzofuran-4-carboxamide |
| INCHI | 1S/C34H48N4O4/c1-7-26-29(38(8-2)25-11-15-41-16-12-25)19-31-27(18-30(42-31)24-9-13-37(14-10-24)21(3)4)32(26)34(40)35-20-28-22(5)17-23(6)36-33(28)39/h17-19,21,24-25H,7-16,20H2,1-6H3,(H,35,40)(H,36,39) |
| InChi Key | NYWVSLBALKNFJR-UHFFFAOYSA-N |
| Smiles | CCC1=C(C2=C(C=C1N(CC)C3CCOCC3)OC(=C2)C4CCN(CC4)C(C)C)C(=O)NCC5=C(C=C(NC5=O)C)C |
| Isomeric SMILES | CCC1=C(C2=C(C=C1N(CC)C3CCOCC3)OC(=C2)C4CCN(CC4)C(C)C)C(=O)NCC5=C(C=C(NC5=O)C)C |
| 分子量 | 576.77 |
| Reaxy-Rn | 32322676 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=32322676&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 30 mg/mL (52.01 mM); Ethanol: 13 mg/mL (22.53 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 30 |
| DMSO(mM) Max Solubility | 52.0138009951974 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 576.800 g/mol |
| XLogP3 | 5.300 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 9 |
| 精确质量Exact Mass | 576.368 Da |
| 单同位素质量Monoisotopic Mass | 576.368 Da |
| 拓扑极表面积Topological Polar Surface Area | 87.100 Ų |
| 重原子数Heavy Atom Count | 42 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1030.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
¥1,999.90
| 1. Lu B, Shen X, Zhang L, Liu D, Zhang C, Cao J, Shen R, Zhang J, Wang D, Wan H et al.. (2018) Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.. ACS Med Chem Lett, 9 (2): (98-102). [PMID:29456795] |